stockrow
Saturday 7 November 2026
Export QNTM’s income statement to Excel — free account
Quantum Biopharma Ltd.
QNTM Healthcare Biotechnology
- EPS
- +85.5%
- Free cash flow
- +5.88%
Quarter to June 2026, against a year earlier
2.11
0.00
0.00%
Follow QNTM
Alert me
Quantum Biopharma Ltd. (QNTM) P/E ratio
Quantum Biopharma Ltd. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2019 | 0.0× | — |
| Sep 2019 | 0.0× | — |
| Jun 2019 | 0.0× | — |
| Mar 2019 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACTU Actuate Therapeutics, Inc. compare | n/m |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR compare | n/m |
| JSPR Jasper Therapeutics, Inc. compare | n/m |
| ESLA Estrella Immunopharma, Inc. compare | n/m |
| ALLR Allarity Therapeutics, Inc. compare | n/m |
| KTTA Pasithea Therapeutics Corp. compare | n/m |
| QNTM Quantum Biopharma Ltd. | n/m |
| NCEL NewcelX Ltd. compare | n/m |
| CNTX Context Therapeutics Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)